A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 43, Issue 1, 2016, Pages 99-109

  Akil, Ayman ^a   Bies, Robert R ^a,k   Pollock, Bruce G ^b   Avramopoulos, Dimitrios ^c   Devanand, D P ^d   Mintzer, Jacobo E ^e   Porsteinsson, Anton P ^f   Schneider, Lon S ^g   Weintraub, Daniel ^h   Yesavage, Jerome ⁱ   Shade, David M ^j   Lyketsos, Constantine G ^c  

^a INDIANA UNIVERSITY   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Roper St Francis Healthcare   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

Agitation; Alzheimer s disease; Citalopram; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; NORCITALOPRAM;

AGED; AGING; ALGORITHM; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; CHEMISTRY; COMPLICATION; DOSE RESPONSE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; RESTLESSNESS; SEXUAL DEVELOPMENT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALGORITHMS; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PSYCHOMOTOR AGITATION; SEX CHARACTERISTICS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84955345243     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-015-9457-6     Document Type: Article

References (36)

1. Ballard C, Corbett A (2013) Agitation and aggression in people with Alzheimer’s disease. Curr Opin Psychiatry 26(3):252–259. doi:10.1097/YCO.0b013e32835f414b
2. Ackerman K, Dimartini A (2015) Psychosomatic medicine. Oxford University Press
3. Kalore AN, Medappa D, Ranjit E, Nayak ES (2015) Safety and efficacy of pharmacological management of agitation in Alzheimer’s dementia - a review. Int J Health Rehabil Sci 4(1):65–72
4. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Cit ADRG (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7):682–691. doi:10.1001/jama.2014.93
5. Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Cit ADRG (2014) Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS ONE 9(6):e98426. doi:10.1371/journal.pone.0098426
6. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C (1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transmission 88(2):157–160. doi:10.1007/BF01244820
7. Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167(4):353–362. doi:10.1007/s00213-002-1364-z
8. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C (2012) Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 7:CD006534. doi:10.1002/14651858.CD006534.pub2
9. Pastoor D, Gobburu J (2014) Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 10(1):121–128. doi:10.1517/17425255.2014.863873
10. Colonna L, Andersen HF, Reines EH (2005) A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21(10):1659–1668. doi:10.1185/030079905X65484
11. Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7(4 Suppl 1):40–44
12. Schatzberg AF, Nemeroff CB (2013) Essentials of clinical psychopharmacology. American Psychiatric Pub
13. Pollock BG (2001) Citalopram: a comprehensive review. Expert Opin Pharmacother 2(4):681–698. doi:10.1517/14656566.2.4.681
14. Fredericson Overø K, Toft B, Christophersen L, Gylding-Sabroe JP (1985) Kinetics of citalopram in elderly patients. Psychopharmacology 86(3):253–257. doi:10.1007/BF00432209
15. Gutierrez M, Abramowitz W (2000) Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy J Human Pharm Drug Ther 20(12):1441–1447. doi:10.1592/phco.20.19.1441.34851
16. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG (2004) Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 44(12):1352–1359. doi:10.1177/0091270004269647
17. Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Muller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR (2010) Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 50(1):62–72. doi:10.1177/0091270009337946
18. Duffull SB, Wright DF, Winter HR (2011) Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol 71(6):807–814. doi:10.1111/j.1365-2125.2010.03891.x
19. Rocha A, Marques MP, Coelho EB, Lanchote VL (2007) Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. Chirality 19(10):793–801. doi:10.1002/chir.20452
20. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B (1997) Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 33(1):109–112
21. Rao N (2007) The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46(4):281–290
22. Tanum L, Strand LP, Refsum H (2010) Serum concentrations of citalopram - dose-dependent variation in R- and S-enantiomer ratios. Pharmacopsychiatry 43(5):190–193. doi:10.1055/s-0030-1254106
23. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9(7):686–692. doi:10.1002/(SICI)1520-636X(1997).9:7<686:AID-CHIR9>3.0.CO;2-5
24. Reis M, Lundmark J, Bengtsson F (2003) Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther Drug Monit 25(2):183–191
25. Reis M, Olsson G, Carlsson B, Lundmark J, Dahl ML, Walinder J, Ahlner J, Bengtsson F (2002) Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 22(4):406–413
26. de Mendonca Lima CA, Baumann P, Brawand-Amey M, Brogli C, Jacquet S, Cochard N, Powell-Golay K, Eap CB (2005) Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry 29(6):952–956. doi:10.1016/j.pnpbp.2005.06.001
27. Ho T, Bies R, Mulsant BH, Devanand DP, Mintzer J, Porsteinsson A, Schneider DW, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos C, Pollock BG (2015) Effect of treatment time and citalopram enantiomer levels on agitation and QTc interval in patients with Alzheimer disease. In: American Pyschaitric Association Annual Meeting Toronto, Canada
28. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L (2003) Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 56(4):415–421
29. Chang M, Tybring G, Dahl ML, Lindh JD (2014) Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet 53(9):801–811. doi:10.1007/s40262-014-0162-1
30. Fudio S, Borobia AM, Pinana E, Ramirez E, Tabares B, Guerra P, Carcas A, Frias J (2010) Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 626(2–3):200–204. doi:10.1016/j.ejphar.2009.10.007
31. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH (2003) Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 31(10):1255–1259. doi:10.1124/dmd.31.10.1255
32. Sanchez C (2006) The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99(2):91–95. doi:10.1111/j.1742-7843.2006.pto_295.x
33. Sanchez C, Kreilgaard M (2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77(2):391–398
34. Sanchez C, Gruca P, Papp M (2003) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14(5–6):465–470. doi:10.1097/01.fbp.0000087733.21047.60
35. Sanchez C, Gruca P, Bien E, Papp M (2003) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75(4):903–907
36. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004) R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142(1):172–180. doi:10.1038/sj.bjp.0705738